Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03069495 · ClinicalTrials.gov registry record
Role of Circulating Innate Lymphoid Cells in Allergic Disorders
A clinical trial, sponsored by University of Nebraska.
- Terminated
- Registry status
- 18
- Enrollment target
NCT03069495: Clinical Trial study, sponsored by University of Nebraska.
NCT03069495 is a clinical trial that was terminated before completion, run by University of Nebraska. The registered enrollment target is 18 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03069495 was terminated before completion, sponsored by University of Nebraska.
- TERMINATED
- Registry status
- 18 participants
- Enrollment target
Study Summary
This study evaluates blood type 2 innate lymphoid cells in participants with mild to moderate asthma and participants with chronic urticaria as compared to healthy adult participants.
Primary Outcome
Blood ILC2s responsiveness will be determined solely for research purposes using ex vivo stimulation assays.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2017-08-21 |
| Est. Completion | 2020-02-24 |
Why NCT03069495 stopped before completion
NCT03069495 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 18 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT03069495 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03069495 about?
NCT03069495 is a clinical study titled "Role of Circulating Innate Lymphoid Cells in Allergic Disorders". This study evaluates blood type 2 innate lymphoid cells in participants with mild to moderate asthma and participants with chronic urticaria as compared to healthy adult participants.
What is the current status of trial NCT03069495?
This trial is currently terminated. The enrollment target is 18 participants. The study started on 2017-08-21. Estimated completion is 2020-02-24.
Who is sponsoring clinical trial NCT03069495?
This trial is sponsored by University of Nebraska, which has 407 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01245179 · 18 participants · Phase 1
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
- NCT01999361 · 18 participants · NA
Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss
- NCT02359825 · 18 participants · Phase 1
Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function
- NCT02870244 · 18 participants · Phase 1
Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI